OptiBiotix Health Plc announced earnings guidance for the fiscal year 2019. The company anticipated further revenue growth in 2019 as existing deals contribute to full year revenues, and partners continue to grow sales. More of the company's existing agreements will start to generate revenues this year, particularly with larger partners launching products in international markets in 2019, and new agreements continue to be signed in 2019. The company anticipated further revenue growth will occur from its online platform (OPTIBIOTIX.Online), SlimBiome® Medical.